La bibliographie complète de RisqueCV.fr
Recommandations
- ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2019
- ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2021
- ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal 2023
- ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal 2024
- ESC/EAS Focused Update of the 2019 Guidelines for the management of dyslipidaemias. European Heart Journal 2025
Critiques des recommandations
Scores de calcul du risque cardiovasculaire
▸ Estimation du risque à 10 ans
- Hageman SHJ, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal 2021
- De Vries TI, et al. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. European Heart Journal 2021
- Pennells L, et al. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. European Heart Journal 2023
- Hageman SHJ, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. European Heart Journal 2022
▸ Estimation du risque sur toute la vie
- Hageman SHJ, et al. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. European Journal of Preventive Cardiology 2024
- Østergaard HB et al. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). European Journal of Preventive Cardiology 2023
- Kaasenbrood L et al. Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART‐REACH Model. JAHA 2018
Bénéfice des traitements
▸ Hypercholestérolémie et hypolipémiants
1) Diminution du LDL
- Cholesterol Treatment Trialists (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012
- Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet 2019
- Cholesterol Treatment Trialists (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. The Lancet Diabetes & Endocrinology 2016
- Hageman SHJ, et al. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Supplementary material Page 25 European Journal of Preventive Cardiology 2024
- Østergaard HB et al. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Supplementary material Page 7 European Journal of Preventive Cardiology 2023
2) Statines
- Law MR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003
- Leiter LA, et al. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007
- Jaam M, et al. Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of Comparative Effectiveness Research 2023
3) Ézétimibe
- Banach M, et al. Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clinic Proceedings 2025
- Pandor A, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. Journal of Internal Medicine 2009
- Mikhailidis DP, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 2011
- Lee J, et al. Effect of Ezetimibe Added to High-Intensity Statin Therapy on Low-Density Lipoprotein Cholesterol Levels: A Meta-Analysis. Cardiology Research 2021
▸ HTA
- Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet 2016
- Hageman SHJ, et al. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Supplementary material Page 25 European Journal of Preventive Cardiology 2024
- Østergaard HB et al. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Supplementary material Page 7 European Journal of Preventive Cardiology 2023
▸ Tabac
Bientôt disponible.
▸ Régime alimentaire
Bientôt disponible.
▸ Activité physique
Bientôt disponible.
Facteurs de risque additionnels
▸ Antécédents familiaux de maladie cardiovasculaire
Bientôt disponible.
▸ Obésité
Bientôt disponible.
▸ Sédentarité
Bientôt disponible.
▸ Mauvais régime alimentaire
Bientôt disponible.
▸ Alcool
Bientôt disponible.
▸ Fibrillation auriculaire
Bientôt disponible.
▸ Insuffisance cardiaque
Bientôt disponible.
▸ Cancer
Bientôt disponible.
▸ BronchoPneumopathie Chronique Obstructive (BPCO)
Bientôt disponible.
▸ Syndrome d’Apnée Obstructive du Sommeil (SAOS)
- Benjafield AV, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. The Lancet Respiratory Medicine 2019
- Fu Y, et al. Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment. Sleep and Breathing 2017
- Benjafield AV, et al. Positive airway pressure therapy and all‐cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies. The Lancet Respiratory Medicine 2025
▸ Insomnie et hypersomnie
- Yin J, et al. Relationship of Sleep Duration With All‐Cause Mortality and Cardiovascular Events: A Systematic Review and Dose‐Response Meta‐Analysis of Prospective Cohort Studies. JAHA 2017
- Sofi F et al. Insomnia and risk of cardiovascular disease: a meta-analysis. European Journal of Preventive Cardiology 2014
▸ Maladie inflammatoire
Bientôt disponible.
▸ Infection par VIH
Bientôt disponible.
▸ Grippe et vaccination antigrippale
- Kwong JC, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. The New England Journal of Medicine 2018
- De Boer AR, et al. Influenza Infection and Acute Myocardial Infarction. NEJM Evidence 2024
- Smeeth L, et al. Risk of Myocardial Infarction and Stroke after Acute Infection or Vaccination. The New England Journal of Medicine 2004
- Udell JA, et al. Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients. JAMA 2013
- Barnes M, et al. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart BMJ 2015
- Fröbert O, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. AHA Circulation 2021
- Zahhar JA, et al. Influenza vaccine effect on risk of stroke occurrence: a systematic review and meta-analysis. Frontiers in Neurology 2024
▸ Trouble psychique
Bientôt disponible.
▸ Stress
Bientôt disponible.
▸ Migraine (avec ou sans aura)
- Mahmoud AN, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 2018
- Adelborg K, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 2018
- Champaloux SW, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. American Journal of Obstetrics and Gynecology 2017
▸ Pré-éclampsie
Bientôt disponible.
▸ Dysfonction érectile
- Baumhäkel M, Böhm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. International Journal of Clinical Practice 2007
- Fan Y, et al. Erectile dysfunction and risk of cardiovascular and all-cause mortality in the general population: a meta-analysis of cohort studies. World Journal of Urology 2018
- Vlachopoulos CV, et al. Prediction of Cardiovascular Events and All-Cause Mortality With Erectile Dysfunction. Circulation: Cardiovascular Quality and Outcomes 2013
- Diaconu CC, et al. The erectile dysfunction as a marker of cardiovascular disease: a review. Acta Cardiologica 2019
- Kessler A, et al. The global prevalence of erectile dysfunction: a review. BJU International 2019
- Baumhäkel M, et al. Cardiovascular Risk, Drugs and Erectile Function – A Systematic Analysis. International Journal of Clinical Practice 2011
- Imprialos KP, et al. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology 2018
▸ Ethnie
Bientôt disponible.
▸ Score calcique
Bientôt disponible.
▸ Fragilité
Bientôt disponible.
▸ Gradient social
- Khaing W, et al. Effects of education and income on cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology 2017
- Bijkerk S, et al. Socioeconomic disparities and risk of recurrent cardiovascular events and cardiovascular disease-free life expectancy in patients with established cardiovascular disease. European Journal of Preventive Cardiology 2025